REG - Eco Animal Health Gp - Appointment of Head of Business Development

ECO Animal HealthAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260414:nRSN2471Aa&default-theme=true

RNS Number : 2471A  Eco Animal Health Group PLC  14 April 2026

14 April 2026

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Appointment of Head of Business Development

Dr Andrew Winder to identify strategic growth opportunities for ECO's R&D
pipeline

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces the appointment of Dr Andrew Winder as
Head of Business Development, effective from 11 May 2026.

 

Andrew brings extensive strategic business development expertise to ECO, with
a proven track record of driving profitable growth across global animal health
markets. Andrew most recently served as Strategic Business Development Lead at
Norbrook Laboratories Ltd (Norbrook), a global provider of veterinary
pharmaceuticals. During his 14-year tenure at Norbrook, Andrew secured
multiple co-development and distribution agreements, created a new global
portfolio strategy that doubled the number of projects in Norbrook's pipeline,
and negotiated distribution agreements with leading multi-national partners
including Boehringer Ingelheim, Zoetis and Elanco.

 

In his new role, Andrew will be responsible for identifying and securing
strategic opportunities, including in-licensing partnerships to grow the
Company's R&D pipeline. His appointment comes at a pivotal time as ECO
progresses the EU commercial launch of its live vaccine for poultry,
ECOVAXXIN® MS, and continues to expand its position as a comprehensive
solutions provider in animal health.

 

Andrew holds a PhD in Pharmaceutical Sciences from the University of Ulster
and a BSc (Hons) in Microbiology from Queens University Belfast. He has also
served as a member of the Board of Directors for Animal Health Europe.

 

David Hallas, Chief Executive Officer of ECO Animal Health, commented: "We are
delighted to welcome Andrew to ECO. His strategic vision, proven ability to
negotiate complex agreements and deep understanding of the animal health
landscape make him a valuable addition to our team. As we advance our R&D
pipeline and expand our commercial footprint, Andrew's expertise in portfolio
management and strategic partnerships will be instrumental in driving our next
phase of growth."

 

Dr Andrew Winder, newly appointed Head of Business Development, added: "I am
excited to be joining ECO at a crucial inflection point in the Company's
evolution. ECO has built an impressive foundation with Aivlosin(®) and is now
bringing innovative products from its proprietary R&D pipeline to market
and I look forward to working with the talented team to identify growth
opportunities that will strengthen ECO's position as leader in animal health."

 

-Ends-

 

Contacts

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Jalini Kalaravy

 Samed Ethemi

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASFDFDDEMSEFL



            Copyright 2019 Regulatory News Service, all rights reserved